carboprostacyclin

Subscribe to Selected New Research on carboprostacyclin

21 relevant articles (0 outcomes, 2 trials/studies) found for this Bio-Agent

Description: potent stable prostacyclin analog which inhibits platelet aggretation; do not confuse with carboprost (15-methyl-PGF2alpha); RN given refers to (3aS-(2Z,3aalpha,4alpha(1E,R*),5beta,6aalpha))-isomer; structure given in first source

Also Known As:

(5E)-6a-carba-prostaglandin I2; 6,9-methano PGI2; 6,9-methano-PGI2; 6,9-methanoprostaglandin I2; 6a-carba-PGI2; 9alpha-deoxy-9alpha-methylene-PGI2; carba PGX; carba-prostacyclin; carbacyclin; carbacycline; carboprostacyclin, (3aS-(2Z,3aalpha,4alpha,(1E,3R*),5beta,6aalpha))-isomer; carboprostacyclin, monosodium salt; Pentanoic acid, 5-(hexahydro-5-hydroxy-4-(3-hydroxy-1-octenyl)-2(1H)-pentalenylidene)-, (3aS-(2E,3aalpha,4alpha(1E,3R*),5beta,6aalpha))-

Bio-Agent Context: Research Results

Related Diseases

1.	Ischemia 05/01/1985 - "It is concluded that the vasodilatory properties of prostacyclin and carbacyclin, together with their known platelet antiaggregatory properties, warrant further study in problem areas of microsurgery such as flap ischemia" 02/01/1991 - "Prostacyclin, the stable prostacyclin analogue carbacyclin, the thromboxane synthetase inhibitor UK-38,485, and the phosphodiesterase inhibitor dipyridamole were tested on rabbit epigastric free flaps for their ability to improve flap survival after a period of ischemia" Order ALL the reference details at left...
2.	Neoplasms (Cancer) 01/01/1987 - "Inhibition of tumor cell induced platelet aggregation by prostacyclin and carbacyclin: an ultrastructural study." 01/01/1987 - "We report here that prostacyclin and carbacyclin inhibit both aggregation and the ultrastructural changes associated with tumor cell-platelet interactions." 01/01/1987 - "Carbacyclin inhibition of tumor cell induced platelet aggregation was longer in duration but carbacyclin was 10-fold less effective than was prostacyclin" 01/01/1987 - "Prostacyclin and carbacyclin inhibited tumor cell platelet interactions in a dose-dependent manner" 01/01/1987 - "Prostacyclin and its synthetic analog carbacyclin were compared as to their abilities to inhibit tumor cell-platelet interactions" Order ALL the reference details at left...
3.	Adhesions 01/01/1988 - "Carbacyclin inhibited all morphological manifestations of platelet activation associated with adhesion: conversion of native discoid platelets to spherical ones on CSC; massive spreading on CIV; and aggregate formation on CI/CIII" 01/01/1988 - "Carbacyclin in the concentrations inducing a 10-fold rise in platelet cAMP did not affect the adhesion of platelets to weak substrates, CV and CSC, but reduced the adhesion to strong substrates, CIV (by 49%) and CI/CIII (by 78%), which stimulated massive spreading and formation of surface-bound aggregates respectively" 05/01/1995 - "Although carbacyclin and HHT had no effect on the adherence process, both 15-HETE and 15-HPETE (10 pmol/L to 100 nmol/L) stimulated RBC adhesion to capillary endothelium" 02/22/1988 - "Platelet adhesion to GD3 decreased significantly in the presence of the stable prostacyclin analogue, carbacyclin." 12/01/1982 - "Both PGI2 and carbacyclin inhibited platelet-collagen adhesion and caused a rise in the platelet cAMP level" Order ALL the reference details at left...
4.	Myocardial Ischemia (Ischemic Heart Diseases) 07/01/1982 - "We studied the potential therapeutic value of the chemically stable carbacyclin analogue ZK 36 375 during acute myocardial ischemia and compared the cardiovascular and anti- and disaggregatory effects of the compound in vitro and ex vivo" 07/01/1982 - "Dissociation of antiplatelet effects from myocardial cytoprotective activity during acute myocardial ischemia in cats by a new carbacyclin derivative (ZK 36 375)." 10/01/1981 - "The potential therapeutic value of the chemically stable carbacyclin analog ZK 36 374 was studied in acute myocardial ischemia (MI)" 10/01/1981 - "Beneficial effects of a new carbacyclin derivative, ZK 36 374, in acute myocardial ischemia." Order ALL the reference details at left...
5.	Thrombosis (Thrombus) 04/01/1986 - "The potency of CS-570 was about 1/8 that of PGI2 and 6 times that of carbacyclin when infused i.v. CS-570 also decomposed an established thrombus" 10/01/1984 - "The hemodynamic and antithrombotic action of ZK 36374, a stable carbacyclin derivative of prostacyclin, was studied during electrically-induced coronary artery thrombosis in the open chest anesthetized pig" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Epoprostenol (Prostacyclin)
2.	Iloprost (Ventavis)
3.	Octreotide (Sandostatin)
4.	Thromboxane-A Synthase
5.	Somatostatin (Somatotropin Release-Inhibiting Factor)
6.	Ibuprofen (Motrin)
7.	Hydroxyeicosatetraenoic Acids (HETE)
8.	Dipyridamole (Persantine)
9.	Digoxin (Digitek)
10.	Collagen

Best Treatments:
Research Summary Report
on Ischemia

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 2711 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year